Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Medical Ltd. announced pooled results from two first-in-human clinical trials of its Alpha DaRT alpha-radiation therapy for pancreatic ductal adenocarcinoma (PDAC). The trials demonstrated 100% local disease control in 19 evaluable patients with a favorable safety profile, including only 27% experiencing mild, transient device-associated …